Clinical-stage biopharmaceutical company Hoth Therapeutics Inc (NASDAQ:HOTH) on Monday reported positive data from its HT-VA study, conducted under its Cooperative Research and Development Agreement (CRADA) with the US Department of Veterans Affairs and Emory University, demonstrating that parenteral GDNF (Glial Cell-Derived Neurotrophic Factor) directly reprograms liver fat metabolism at the genetic level in a preclinical model of metabolic-associated fatty liver disease (MAFLD).

According to the company, the data highlights statistically significant improvements in key genes responsible for fat production and fat metabolism, positioning GDNF as a potentially differentiated therapeutic approach targeting the root cause of fatty liver disease and metabolic dysfunction.

Next, Hoth plans to advance the HT-VA findings into additional preclinical validation studies, evaluate clinical development pathways for metabolic and liver diseases, and explore strategic partnerships and collaborations to accelerate development.